Brain tumors are the most common solid tumors in children and gliomas are the most common subtype. Despite their relative frequency, malignant gliomas have a 10-fold lower incidence in children compared to adults. As a result, prognostic variables in adults are extrapolated to pediatric patients for treatment decision making and patient counseling. In this review, we outline the known clinical- and treatmentrelated factors associated with outcome in pediatric high-grade glioma (HGG). We define the limitations of using adult HGG to drive pediatric HGG decision making by showing a unique molecular signature and oncogenic pathway in pediatric HGG that is distinct from adult HGG. Biologic determinants of prognosis are reviewed.
|Original language||English (US)|
|Number of pages||7|
|Journal||European journal of Clinical and Medical Oncology|
|State||Published - Dec 1 2012|
ASJC Scopus subject areas